Articles

UCB's Bimzelx vs. AbbVie's Skyrizi: Psoriatic Arthritis Competitive Landscape

UCB's Bimzelx has demonstrated a competitive advantage over AbbVie's Skyrizi in head-to-head psoriatic arthritis trials. This analysis explores the implications for the competitive landscape and pharmaceutical business development.

About Us: Your Partner in Pharmaceutical Innovation

Learn about our mission, vision, and values as a leader in the pharmaceutical industry. We strive to foster innovation and collaboration for better healthcare.

Imfinzi + Imjudo HCC: HIMALAYA Survival Data

AstraZeneca's Imfinzi and Imjudo have shown promising results in early-stage liver cancer at ASCO. This article explores the implications for the pharmaceutical industry.

Direct-to-Patient Pharma: OIG AKS Guardrails

The shift towards direct-to-patient models is reshaping pharmaceutical access. This article explores the implications for pharma teams and the industry at large.

Revolution Medicines RAS Leadership at ASCO

Revolution Medicines showcased its confidence in RAS leadership at ASCO, amidst rising competition. This article explores the implications for the pharma landscape.

Olverembatinib ASCO 2026 CML-CP Update

Ascentage Pharma has unveiled updated clinical data for Olverembatinib at ASCO 2026, highlighting its potential as a second-line therapy in CML-CP. This article delves into the implications for investors and pharma teams.

OS Therapies Acquires Full IP Rights to OST-HER2 for $8M

OS Therapies has acquired full intellectual property rights to its lead drug OST-HER2 for $8 million, along with two additional cancer assets, enhancing its portfolio in immunology vaccines.

Global Biosimilar Market Analysis: Trends and Challenges

This article analyzes the current trends and challenges in the global biosimilar market, highlighting key implications for stakeholders.

Actinogen's EMA Scientific Advice: A Positive Step for Alzheimer's Program

Actinogen has received positive scientific advice from the EMA, aligning with previous FDA guidance for its Alzheimer's disease program. This development signals potential growth opportunities for investors and stakeholders.

LIST Joins EuropaBio: Luxembourg Biotech Signal

The Luxembourg Institute of Science and Technology (LIST) joined EuropaBio on 29 May 2026, expanding the association’s applied-research footprint. For pharma and industrial biotech partners, the move is a signal about Luxembourg’s biomanufacturing ambitions—not a product approval.

Rising Brand-Name Drug Prices in the US: A Global Perspective

This article examines the trend of increasing brand-name drug prices in the US compared to declining prices abroad, highlighting the implications for pharmaceutical companies.

From Promise to Proof: The Shakeup in Today’s Biosimilar Market

This article delves into the evolving landscape of the biosimilar market, highlighting key developments and their implications for stakeholders. Understand the investment opportunities and competitive dynamics shaping the future.

EMA Endorses Novo Nordisk's Wegovy for Weight Loss

The European Medicines Agency has endorsed Novo Nordisk's Wegovy for weight loss, marking a significant milestone in obesity treatment. This analysis explores the implications for investors and pharma teams.

Pfizer's Talzenna Combo: A Game Changer in Prostate Cancer Treatment

Pfizer has made significant strides with its Talzenna combination therapy for castration-sensitive prostate cancer, surpassing Johnson & Johnson. This article delves into the implications of this breakthrough for the pharmaceutical landscape.

Incyte's Strategic Positioning of Monjuvi for First-Line DLBCL

Incyte is strategically positioning Monjuvi for first-line treatment of DLBCL, responding to the competitive landscape of bispecific therapies. This article delves into the implications for pharmaceutical teams and investors.

PharmaEssentia Hires Vogel for Besremi

PharmaEssentia has appointed Eric Vogel, a former Incyte executive, to spearhead the expansion of its drug Besremi. This strategic move highlights the company's growth ambitions in the pharmaceutical sector.

CVS Restores Coverage for Eli Lilly's Obesity Medications

CVS has reinstated coverage for Eli Lilly's obesity medication Zepbound and introduced a new pill, Foundayo. This decision has significant implications for the pharmaceutical market.

EU Panel Endorses Expanded Applications for Cancer Medications

The EMA panel's endorsement for wider uses of cancer drugs marks a significant shift in treatment options, influencing investment strategies and market dynamics. This analysis explores the implications for pharmaceutical stakeholders.

Viridian WuXi Deal Ahead of TED PDUFA

Viridian has engaged WuXi Bio for the supply of its eye drug, Veligrotug, as it awaits an FDA decision. This partnership highlights significant implications for the pharmaceutical landscape.

EMA CHMP May 2026: New Medicine Opinions

The EMA's CHMP has backed four new medicines during its May meeting, marking significant advancements in clinical trials. This analysis explores the implications for investors and pharma teams.